Browsing by Author "Hayes, Richard B."

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Interactions between folate intake and genetic predictors of gene expression levels associated with colorectal cancer risk
    (Springer, 2022-11-07) Haas, Cameron B.; Su, Yu-Ru; Petersen, Paneen; Wang, Xiaoliang; Bien, Stephanie A.; Lin, Yi; Albanes, Demetrius; Weinstein, Stephanie J.; Jenkins, Mark A.; Figueiredo, Jane C.; Newcomb, Polly A.; Casey, Graham; Marchand, Loic Le; Campbell, Peter T.; Moreno, Victor; Potter, John D.; Sakoda, Lori C.; Slattery, Martha L.; Chan, Andrew T.; Li, Li; Giles, Graham G.; Milne, Roger L.; Gruber, Stephen B.; Rennert, Gad; Woods, Michael O.; Gallinger, Steven J.; Berndt, Sonja; Hayes, Richard B.; Huang, Wen-Yi; Wolk, Alicja; White, Emily; Nan, Hongmei; Nassir, Rami; Lindor, Noralane M.; Lewinger, Juan P.; Kim, Andre E.; Conti, David; Gauderman, W. James; Buchanan, Daniel D.; Peters, Ulrike; Hsu , Li; Epidemiology, Richard M. Fairbanks School of Public Health
    Observational studies have shown higher folate consumption to be associated with lower risk of colorectal cancer (CRC). Understanding whether and how genetic risk factors interact with folate could further elucidate the underlying mechanism. Aggregating functionally relevant genetic variants in set-based variant testing has higher power to detect gene-environment (G × E) interactions and may provide information on the underlying biological pathway. We investigated interactions between folate consumption and predicted gene expression on colorectal cancer risk across the genome. We used variant weights from the PrediXcan models of colon tissue-specific gene expression as a priori variant information for a set-based G × E approach. We harmonized total folate intake (mcg/day) based on dietary intake and supplemental use across cohort and case-control studies and calculated sex and study specific quantiles. Analyses were performed using a mixed effects score tests for interactions between folate and genetically predicted expression of 4839 genes with available genetically predicted expression. We pooled results across 23 studies for a total of 13,498 cases with colorectal tumors and 13,918 controls of European ancestry. We used a false discovery rate of 0.2 to identify genes with suggestive evidence of an interaction. We found suggestive evidence of interaction with folate intake on CRC risk for genes including glutathione S-Transferase Alpha 1 (GSTA1; p = 4.3E-4), Tonsuko Like, DNA Repair Protein (TONSL; p = 4.3E-4), and Aspartylglucosaminidase (AGA: p = 4.5E-4). We identified three genes involved in preventing or repairing DNA damage that may interact with folate consumption to alter CRC risk. Glutathione is an antioxidant, preventing cellular damage and is a downstream metabolite of homocysteine and metabolized by GSTA1. TONSL is part of a complex that functions in the recovery of double strand breaks and AGA plays a role in lysosomal breakdown of glycoprotein.
  • Thumbnail Image
    Item
    Smoking Behavior and Prognosis After Colorectal Cancer Diagnosis: A Pooled Analysis of 11 Studies
    (Oxford University Press, 2021-08-31) Alwers, Elizabeth; Carr, Prudence R.; Banbury, Barbara; Walter, Viola; Chang-Claude, Jenny; Jansen, Lina; Drew, David A.; Giovannucci, Edward; Nan, Hongmei; Berndt, Sonja I.; Huang, Wen-Yi; Prizment, Anna; Hayes, Richard B.; Sakoda, Lori C.; White, Emily; Labadie, Julia; Slattery, Martha; Schoen, Robert E.; Diergaarde, Brenda; van Guelpen, Bethany; Campbell, Peter T.; Peters, Ulrike; Chan, Andrew T.; Newcomb, Polly A.; Hoffmeister, Michael; Brenner, Hermann; Community and Global Health, Richard M. Fairbanks School of Public Health
    Background: Smoking has been associated with colorectal cancer (CRC) incidence and mortality in previous studies, but current evidence on smoking in association with survival after CRC diagnosis is limited. Methods: We pooled data from 12 345 patients with stage I-IV CRC from 11 epidemiologic studies in the International Survival Analysis in Colorectal Cancer Consortium. Cox proportional hazards regression models were used to evaluate the associations of prediagnostic smoking behavior with overall, CRC-specific, and non-CRC-specific survival. Results: Among 12 345 patients with CRC, 4379 (35.5%) died (2515 from CRC) over a median follow-up time of 7.5 years. Smoking was strongly associated with worse survival in stage I-III patients, whereas no association was observed among stage IV patients. Among stage I-III patients, clear dose-response relationships with all survival outcomes were seen for current smokers. For example, current smokers with 40 or more pack-years had statistically significantly worse overall, CRC-specific, and non-CRC-specific survival compared with never smokers (hazard ratio [HR] =1.94, 95% confidence interval [CI] =1.68 to 2.25; HR = 1.41, 95% CI = 1.12 to 1.78; and HR = 2.67, 95% CI = 2.19 to 3.26, respectively). Similar associations with all survival outcomes were observed for former smokers who had quit for less than 10 years, but only a weak association with non-CRC-specific survival was seen among former smokers who had quit for more than 10 years. Conclusions: This large consortium of CRC patient studies provides compelling evidence that smoking is strongly associated with worse survival of stage I-III CRC patients in a clear dose-response manner. The detrimental effect of smoking was primarily related to noncolorectal cancer events, but current heavy smoking also showed an association with CRC-specific survival.